PRE vs NTRA vs EXAS vs MYRG

For growth investors, Prenetics Global Limited (PRE) is the stronger pick with 201.

7% revenue growth year-over-year, versus 8. 8% for MYR Group Inc. (MYRG). MYR Group Inc. (MYRG) offers the better valuation at 56. 8x trailing P/E (44. 0x forward), making it the more compelling value choice. Analysts rate Prenetics Global Limited (PRE) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, MYR Group Inc.

is actually cheaper at 44. 0x.

Over the past 5 years, MYR Group Inc.

(MYRG) delivered a total return of +417. 6%, compared to -86. 1% for Prenetics Global Limited (PRE). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus PRE's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus MYR Group Inc. 's 1. 70β — meaning MYRG is approximately 1308% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Prenetics Global Limited (PRE) carries a lower debt/equity ratio of 1% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Prenetics Global Limited (PRE) is pulling ahead at 201.

7% versus 8. 8% for MYR Group Inc. (MYRG). On earnings-per-share growth, the picture is similar: MYR Group Inc. grew EPS 311. 5% year-over-year, compared to -14. 0% for Prenetics Global Limited. Over a 3-year CAGR, PRE leads at 91. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MYR Group Inc.

(MYRG) is the more profitable company, earning 3. 2% net margin versus -63. 1% for Prenetics Global Limited — meaning it keeps 3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MYRG leads at 4. 4% versus -40. 5% for PRE. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, MYR Group Inc.

(MYRG) trades at 44. 0x forward P/E versus 582. 8x for Exact Sciences Corporation — 538. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRE: 126. 8% to $36. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, NTRA: +20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PRE (Healthcare) and NTRA (Healthcare) and EXAS (Healthcare) and MYRG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PRE is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; EXAS is a mid-cap high-growth stock; MYRG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.